An update on maternal medication-related embryopathies

Area of Science:

• Obstetrics and Gynecology
• Pharmacology
• Teratology

Background:

• Limited data on drug efficacy, pharmacokinetics, and teratogenicity complicates pregnancy medication counseling.
• Existing teratogenic drug information often stems from animal studies, case reports, or cohort studies.
• Accurate counseling requires balancing potential fetal risks against untreated maternal health conditions.

Purpose of the Study:

• To review commonly prescribed medications identified as significant human teratogens.
• To provide recommendations for pre-conception and antenatal counseling regarding medication safety.
• To enhance clinician confidence in managing pregnant women's medication needs.

Main Methods:

• Literature review of commonly prescribed medications with known teratogenic potential.
• Synthesis of available data on drug teratogenicity, efficacy, and pharmacokinetics.
• Development of counseling recommendations for healthcare providers.

Main Results:

• Identification of a non-exhaustive list of significant human teratogens.
• Emphasis on the importance of pre-conception counseling for medication optimization.
• Highlighting the need for clinicians to utilize appropriate resources for antenatal care.

Conclusions:

• Effective counseling on pregnancy medication safety is essential.
• Pre-conception planning allows for optimization of medications and chronic condition management.
• Clinicians must be equipped to manage medication use during pregnancy, considering both fetal and maternal health.